• Users Online: 155
  • Print this page
  • Email this page
Year : 2020  |  Volume : 3  |  Issue : 1  |  Page : 34-44

Highlights on the management of oligometastatic disease

1 Department of Oncology, King Abdulaziz Medical City; King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
2 King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
3 Department of Medicine, King Saud University Hospital, Riyadh, Saudi Arabia
4 Department of Radiation Oncology, King Fahad Medical City, Riyadh, Saudi Arabia
5 Al Baha University, Al Baha, Saudi Arabia
6 Department of Radiation Oncology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
7 Radiation Oncology Unit, John Hopkins Aramco Healthcare, Dharan, Saudi Arabia

Correspondence Address:
Salem M Alshehri
Department of Oncology, King Abdulaziz Medical City, P. O. Box: 22490, Riyadh 11426
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JIPO.JIPO_24_19

Get Permissions

Purpose: The understanding of oligometastatic disease (OMD) is rapidly evolving and with this comes the ability to utilize a number of modalities that excel in the localized control of disease. It has been identified that there are no clear guidelines based on high-level evidence to standardized approaches toward the management of OMD. These highlights have been developed to provide a road map for all health-care professionals who are involved in the management of OMD to support standardized patient care. Methods: The Saudi Lung Cancer Guidelines Committee is a part of the Saudi Lung Cancer Association which, in turn, is part of the Saudi Thoracic Society. Considering that lung cancer constitutes a major proportion of OMD prevalence, the committee took the initiative to develop national highlights to support the management of OMD within Saudi Arabia. The committee members are national clinical leaders who collaborated with international expertise to establish these highlights to serve as a general clinical pathway in the management of OMD. Results: Standardization of the indications to diagnose oligometastases and patient selection criteria including ineligibility criteria for treatment are the basis of the highlights. Treatment approaches including surgical and the variety of radiotherapeutical options are discussed in relation to specific oligometastatic sites. Acceptable measurements for response to treatment and the future for the treatment of OMD conclude the development of the highlights. Conclusion: These are the first national highlights addressing this important disease in oncology. The implementation of these highlights as guidelines requires a robust multidisciplinary team and access to specific technology and expertise. These highlights are based on the most recent findings within the literature but will require repeated review and updating due to this rapidly evolving field in disease management.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded161    
    Comments [Add]    

Recommend this journal